Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Roche unveils intelligent automation management solution at 2013 Clinical Lab Expo



Roche unveils intelligent automation management solution at 2013 Clinical Lab
                                     Expo

Advanced system helps medical labs improve efficiency and speed of blood
sample testing

PR Newswire

HOUSTON, July 30, 2013

HOUSTON, July 30, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY)
announced plans today at the AACC 2013 Clinical Lab Expo for the U.S.
introduction of the cobas 8100 automated workflow series, an advanced system
designed to automate many routine tasks to help diagnostic laboratories
increase efficiency, reduce expenses and maximize patient safety.

"This total lab automation solution can make a significant contribution to
effective medical decision-making and higher efficiency in the medical
laboratory," said Jack Phillips, president and CEO of Roche Diagnostics
Corporation. "In addition to helping labs lower costs and minimize the risk of
sample mix-ups, it offers short and predictable turnaround times to help
physicians make fast and reliable treatment decisions for patients."

Using intelligent robotics, the cobas 8100 series automatically prepares blood
samples for immediate testing and post-analytical processing, providing
high-speed processing of up to 1,100 samples per hour. The system offers
dynamic and efficient sample transport options and great flexibility, allowing
labs to automate both routine and STAT tests. Healthcare professionals benefit
from on-time, high quality diagnostic results for both routine and emergency
tests, even at laboratory workload peaks.

The cobas 8100 series can easily be added onto Roche's existing cobas
analyzers, and its flexible, modular design allows labs to grow over time as
demand increases. Market availability in the U.S. is expected in 2015.

In addition to unveiling the cobas 8100 automated workflow series at the
Clinical Lab Expo, Roche is sponsoring two workshops about critical industry
issues in conjunction with the American Association for Clinical Chemistry
(AACC) annual meeting:

 1. Improving Cardiac Test Turnaround Time by Collaboration Between the Lab
    and Emergency Department, a case study discussion by representatives from
    St. John Hospital and Medical Center in Detroit about how collaboration
    contributed to improvements in outcomes and the patient experience.
 2. Hepatitis C Virus in the U.S. from Three Perspectives: Trends, Treatment,
    and Diagnostics, a panel discussion with a laboratorian, an epidemiologist
    and a clinician about key issues in HCV—including the CDC's proposal for
    one-time hepatitis C testing for all baby boomers.

In its booth at the Expo (#4049), Roche will also be exhibiting a variety of
in-vitro and tissue diagnostics solutions designed to enhance testing
efficiency and provide reliable clinical information from central labs to
hospital point of care, clinics and patient homes. Specific product areas
include integrated clinical chemistry and immunoassay analyzers, molecular
diagnostics platforms, lab automation, immunohistochemistry/in situ
hybridization systems, handheld point-of-care testing monitors, and
information technology solutions.

Selected products to be featured in the booth include:

ACCU-CHEK Inform II system—the first POC blood glucose device to offer
meter-level wireless technology for accurate, real-time patient data transfer.

CoaguChek XS Plus System—now CLIA-waived, the handheld PT/INR meter may be
used in labs that do not meet the requirements to perform moderate- or
high-complexity testing.

cobas 4800 System—offering true walk-away automation of nucleic acid
purification, PCR set-up and real-time PCR amplification and detection, the
system also runs the cobas CT/NG Test, the cobas BRAF V600 Mutation Test and
the cobas EGFR Mutation Test.

cobas 8000 modular analyzer series—third-generation integrated analyzer series
that resets the standard for speed and efficiency in high-volume chemistry and
immunoassay testing.

MODULAR PRE-ANALYTICS (MPA) system—a turnkey automation solution designed for
labs that seek greater consolidation by connecting with Roche integrated
analytics.

cobas 6500 analyzer series*—fully automated solution for urinalysis testing.

*In development; not available for sale in the U.S.

cobas b 221 system—point-of-care blood gas analyzer that offers optimal
reliability to help hospital staff provide outstanding patient care.

cobas p 312 and cobas p 612 pre-analytical systems—front-end automation
solutions that offer comprehensive, vendor-neutral sample management to help
labs improve workflow.

cobas IT 1000 connectivity solution—data management for point-of-care testing.

BenchMark ULTRA platform with Ultimate Reagent Access (URA)—the world's first
platform that allows labs to stain individual IHC and ISH slides as soon as
they arrive, improving sample turnaround time.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company, with truly differentiated medicines in
oncology, infectious diseases, inflammation, metabolism and neuroscience.
Roche is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. Roche's personalized
healthcare strategy aims at providing medicines and diagnostic tools that
enable tangible improvements in the health, quality of life and survival of
patients. In 2012 Roche had over 82,000 employees worldwide and invested over
8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss
francs. Genentech, in the United States, is a wholly owned member of the Roche
Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For
more information, please visit www.roche.com or www.roche-diagnostics.us.

All trademarks mentioned in this release are protected by law.

For further information, please contact:

Todd Siesky
Director, Corporate Communications  

Roche Diagnostics Corporation

Indianapolis, Indiana USA
(317) 521-3966
todd.siesky@roche.com

 

SOURCE Roche Diagnostics

Website: http://www.roche.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement